Trastuzumab Deruxtecan (indication: breast cancer, HER2+, ≥ 2 prior therapies)



  • Active Sustance: Trastuzumab Deruxtecan
  • Name: Enhertu®
  • Therapeutic area: Breast cancer
  • Pharmaceutical company: Daiichi Sankyo Deutschland GmbH


Time table:

  • Start: 01.08.2022
  • Publication of assessment: 01.11.2022
  • End of public hearing: 22.11.2022
  • Final decision by G-BA: middle of January 2023


Comparative therapy:

  • Therapy at the physician's discretion, appropriate therapies include:
    - lapatinib in combination with capecitabine OR
    - trastuzumab in combination with lapatinib (only for patients with hormone receptor-negative breast cancer) OR
    - trastuzumab in combination with capecitabine